ストックスクリーナーアプリを入手
110.83
1.60%
1.75
Abbott Laboratories (ABT) 最新ニュース
Abbott Laboratories (ABT): Short-Term Headwinds, Strategic Pipeline Strength, and UBS Buy Rating - Finviz
Abbott stock price: what to watch Monday after FDA Libre recall update, insider buy - TechStock²
Analysts’ Top Healthcare Picks: Mettler-Toledo (MTD), Abbott Laboratories (ABT) - The Globe and Mail
Top Abbott Insider Quietly Makes a Bold Million-Dollar Move - TipRanks
Abbott Labs CEO makes $2M bet as stock sinks - thestreet.com
Abbott Laboratories Announces Measurable Results From LATAM Diagnostic Market Development and Training Initiative Led by Claudia Marcela Riaño Caro - PRWeb
Exact Sciences (EXAS) Advances as HSR Period Expires for Abbott Deal - GuruFocus
Abbott studies support pulsed field ablation, dual ablation catheters - MassDevice
Abbott Stock: 2026 Recovery Outlook After a 17% Decline - TIKR.com
Abbott (ABT) Showcases Promising AFib Therapy Advances at Boston Symposium - GuruFocus
Abbott reports positive results from study on its atrial fibrillation therapies - AlphaStreet News -
Abbott Laboratories (ABT) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance Singapore
Abbott’s atrial fibrillation treatments show strong results in new studies By Investing.com - Investing.com India
Abbott Labs director Starks buys shares worth $1.08 million By Investing.com - Investing.com India
Catheter trials show Abbott devices cut AFib episodes for most patients - stocktitan.net
UK’s NICE recommends Abbott’s Cardiomems heart failure system - BioWorld MedTech
Abbott on track with dual sensor, FDA warns on FreeStyle Libre - Modern Healthcare News
BTIG Reaffirms Their Buy Rating on Abbott Laboratories (ABT) - The Globe and Mail
US FDA says injuries from Abbott’s recalled glucose sensors reach 860 - WHTC
Abbott Laboratories: How a 136-Year-Old Medtech Giant Is Re?Engineering the Future of Diagnostics an - AD HOC NEWS
Analysts Offer Insights on Healthcare Companies: Abbott Laboratories (ABT) and Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
US FDA says injuries from Abbott's recalled glucose sensors reach 860 - marketscreener.com
Abbott recalls glucose sensors after seven deaths linked to faulty readings - marketscreener.com
Abbott Laboratories (ABT) Faces FDA's Most Serious Recall Over G - GuruFocus
Abbott glucose monitor recall classified as most serious (ABT) - Seeking Alpha
Do Wall Street Analysts Like Abbott Laboratories Stock? - Yahoo Finance
FDA demands better response from Abbott over Libre inspection violations - Fierce Biotech
Hantz Financial Services Inc. Sells 29,746 Shares of Abbott Laboratories $ABT - MarketBeat
Envestnet Asset Management Inc. Sells 169,808 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Now 18% Cheaper, Time To Buy - Trefis
Gains Report: Can Abbott Laboratories sustain earnings growthDay Trade & Safe Investment Capital Preservation Plans - baoquankhu1.vn
Abbott receives FDA warning letter related to FreeStyle Libre CGMs - MassDevice
2 Healthcare Dividend Stocks That are Just What the Doctor Ordered - The Motley Fool
Abbott Faces FDA Scrutiny On FreeStyle Libre And Broader Quality Story - Yahoo Finance
Abbott (ABT) stock slips on FDA warning letter over FreeStyle Libre testing; dates to watch - TechStock²
Abbott CEO Share Purchase Highlights $21b Exact Sciences Deal And Valuation - simplywall.st
Abbott receives FDA warning letter over Freestyle Libre CGMs - MedTech Dive
Abbott (ABT) Faces Profit Headwinds as Pediatric Nutrition Remains Under Pressure - Finviz
OTC/DTC Infectious Disease Diagnostics Research Report 2026: Market Strategies, Trends, and Forecasts 2025-2029 - GlobeNewswire Inc.
Sollinda Capital Management LLC Sells 15,866 Shares of Abbott Laboratories $ABT - MarketBeat
Jones Financial Companies Lllp Buys 61,627 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Stake Lessened by Thrivent Financial for Lutherans - MarketBeat
Abbott Laboratories (ABT): A Bull Case Theory - Insider Monkey
Abbott (ABT) Sees Increased Bearish Options Activity - GuruFocus
Abbott (ABT) stock price steadies after Barclays trims target; Exact Sciences vote is next key date - TechStock²
Abbott’s Exact Sciences Deal Recasts Diagnostics While Nutrition Faces Reset - Yahoo Finance
Abbott stock price today: ABT slips after Barclays cuts target as Wall Street resets expectations - TechStock²
The Best Dividend King to Buy With $150 - AOL.com
ABT: Barclays Adjusts Abbott Laboratories Price Target to $142 | - GuruFocus
Abbott Laboratories (NYSE:ABT) Price Target Cut to $142.00 by Analysts at Barclays - MarketBeat
Abbott: Long-Term Investment Opportunity For Dividend Growth Investors - Seeking Alpha
Barclays Cuts Price Target on Abbott Laboratories to $142 From $169, Maintains Overweight Rating - marketscreener.com
Abbott has 2-year data supporting Tendyne mitral valve replacement - MassDevice
Mawer Investment Management Ltd. Has $168.20 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Barclays Maintains Abbott Laboratories(ABT.US) With Buy Rating, Cuts Target Price to $142 - 富途牛牛
Abbott stock price rebounds 3% after Friday rally as analysts cut targets; what’s next for ABT - TechStock²
Assessing Abbott Laboratories (ABT) Valuation After Q4 Nutrition Weakness And Ongoing Device Strength - simplywall.st
Decent organic sales growth expected for Abbott Laboratories (ABT) in 2026 - MSN
Principal Financial Group Inc. Sells 331,362 Shares of Abbott Laboratories $ABT - MarketBeat
Mediolanum International Funds Ltd Acquires 169,026 Shares of Abbott Laboratories $ABT - MarketBeat
1.14%
0.78%
大文字化:
|
ボリューム (24 時間):